Nanobiotix (NASDAQ:NBTX) Sets New 52-Week High – What’s Next?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX)’s stock price reached a new 52-week high during mid-day trading on Saturday . The company traded as high as $31.62 and last traded at $31.04, with a volume of 86067 shares changing hands. The stock had previously closed at $27.51.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on NBTX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Nanobiotix in a report on Thursday, January 22nd. HC Wainwright reissued a “buy” rating on shares of Nanobiotix in a research note on Tuesday, November 4th. Leerink Partners reaffirmed an “outperform” rating on shares of Nanobiotix in a research note on Tuesday, November 25th. TD Cowen initiated coverage on Nanobiotix in a research report on Friday, February 6th. They set a “buy” rating for the company. Finally, Guggenheim lifted their price target on shares of Nanobiotix from $8.00 to $26.00 and gave the stock a “buy” rating in a research report on Friday, February 6th. Four investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat, Nanobiotix has an average rating of “Moderate Buy” and a consensus target price of $20.00.

Nanobiotix Stock Up 12.8%

The company has a 50 day simple moving average of $22.88 and a 200-day simple moving average of $19.32.

Hedge Funds Weigh In On Nanobiotix

Several hedge funds have recently made changes to their positions in the business. Royal Bank of Canada raised its holdings in shares of Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares during the last quarter. Millennium Management LLC bought a new position in Nanobiotix in the fourth quarter valued at $390,000. Marshall Wace LLP bought a new position in Nanobiotix in the fourth quarter valued at $220,000. Finally, Optiver Holding B.V. acquired a new stake in Nanobiotix in the 3rd quarter valued at $101,000. 38.81% of the stock is owned by institutional investors.

About Nanobiotix

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.